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The business of unproven cellular therapies
The market of “medical tourism” that broadly in-
cludes patients who travel for cheaper treatments
because of the high cost of care in their own coun-
tries is approximately $20 to $60 billion and growing
at constant rate [1,2].We can estimate that the market
for unproven cellular therapies can vary between $300
million and $2.4 billion on the basis of recent anal-
yses reporting that more than 60,000 patients are
treated every year with unproven cellular therapies [3],
with an estimated charge for those procedures between
$5,000 and $40,000 each [4]. Although these are sig-
nificant numbers, in all likelihood most unproven
cellular therapies will generate no predictable benefit
for patients, despite the fact that in some countries
the business of unproven cellular therapies is partly
supported by governmental development strategies [5].
As previously described, there is a long and “in-
glorious” tradition of bogus medical treatment offerings
for needy patients, predating the field of cellular therapy
[6]. Unfortunately, presumed medical innovations, often
prematurely described in the lay press as “treat-
ments,” quickly become the anticipated standard of
care in the public eye and for patients who are often
desperately looking for novel interventions.There are
many factors limiting the diffusion and successful com-
mercialization of cellular therapies; however, the
ultimate success of the field is dependent on the level
of regulation, in both the pre-marketing and in post-
marketing phases of product development and
translation. Without sufficient regulatory controls in
place, unscrupulous commercial entities might be able
to upset the commercial balance with unsubstanti-
ated claims and unethical marketing practices. In
addition, if patients are physically or economically
harmed, there will be a detrimental effect further in-
hibiting the commercialization of cellular therapies.
In fact, if efficacy is never established and
side effects are documented, then commercial
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entities will be hindered in their ability to generate a
solid business case that could benefit industry, the
biomedical field, society worldwide, and—most
important—patients.
Furthermore, the market for unproven cellular
therapies is volatile, particularly given that these thera-
pies are often associated with countries with developing
economies. A series of factors, including economic and
political instability, policy changes, restrictions on travel,
and advertising practices, contribute to such
uncertainty [3].
Investors understand the difference between un-
proven cellular therapies and therapies that have been
evaluated in a thorough development and regulatory
process. They do not want to be associated with ap-
proaches that may be perceived as unethical, with
uncertain risks and benefits, and that may be pro-
moted in a misleading manner. Therefore, unproven
cellular therapies, which are marketed as safe and ef-
fective, can have a destabilizing influence on financial
sector confidence that emerging cell therapeutics are
well founded and ready for development. These ap-
proaches, which lack an evidence-based development
process, erode confidence that core therapeutic hy-
potheses have been validated.This further exacerbates
concerns that scientific platforms are adequately
durable to support clinical proof of concept, and
therefore further restricts investment decisions
in the cell therapy space. It is important for inves-
tors to understand the regulatory pathway for
development of cellular therapies. For a typical in-
vestor, predictability and milestone achievements are
critical to management of ongoing investments. The
unethical commercialization of cellular therapies com-
plicates the development pathway for an ethical
developer and introduces an unpredictable factor into
an investor’s decision to invest in a cell therapy
company.
For these reasons, it is difficult to identify big mul-
tinational players in the unproven cellular therapies
field; more often, small to medium enterprises are in-
volved with manufacturing sites located close to or in
the same clinic where the patients are treated. Thus,
cell manipulation and administration can take place
within the same structure or institution, creating a sense
of security about a product generated in house (“home-
made”) and, therefore, apparently more controlled.This
goes back to the “black box of unproven cellular thera-
pies manufacturing” and to the challenges for both
established and under-development regulatory frame-
works, as already discussed in Parts 3 and 4.
This “homemade” manufacturing model favors the
gray area where unproven cellular therapies can pro-
liferate with several advantages for the companies
involved. A localized manufacturing process is less
visible and less subject to regulatory and scientific
scrutiny, a situation that typically characterizes these
approaches. In addition, the entire process executed
within a single clinic can provide the impression of a
“compassionate use” that, without identifiable scien-
tific bases and proper information, may be useless and
even harmful. Finally, this model of unproven cellu-
lar therapies features a business model where cell
manipulation takes place at relatively low produc-
tion costs due to the limited controls introduced during
the manufacturing process, and without investment
into complex logistics or storage apparatus and
procedures.
Advancing cell therapeutics to commercializa-
tion and standard of care requires significant capital
investment from pharma and health care, and to date,
although investments in the field are progressively in-
creasing, they have been somewhat cautious. Investors
are looking for predictability in a validated business
model, an attribute that is currently growing in the
field of cellular therapy but that is put in danger when
discussing unproven cellular interventions. Industry
players realize the importance of validation of key
market segments, such as the ones for mesenchymal
stromal cells or chimeric antigen receptorT cells.These
are healthy signs reflecting a maturation that cannot
be hindered by unethical, unproven, only-for-profit–
based cell therapeutic procedures.
Unproven cellular therapies, medical
innovation and commercialization
One of the most frequent claims supporting un-
proven cellular therapies is that those strategies carry
the unique opportunity to rapidly transfer promising
cell-based therapeutic approaches for still-unmet clin-
ical needs.This not only represents a marketing strategy
“to sell” these products, it is also aimed at convinc-
ing society and patients of the innovative nature of
the unproven cell therapy and to support the false
concept that medical innovation is slowed, or even
stopped, by consolidated regulatory frameworks.
However, we contend that many unproven cell thera-
pies are actually anti-innovative. We are naturally
supportive of scientific and medical innovations in
cellular therapies; however, we do not consider un-
proven cellular therapies as a solution for still
unanswered medical questions.The last Internation-
al Society for Cellular Therapy (ISCT) paper on the
topic ([7], p. 966) stated: “Medical innovation in cel-
lular therapy may be viewed as ethical and legitimate
use of non-approved cell therapy by qualified health-
care professionals in their practice of medicine. Patients
not eligible for controlled clinical trials should be able
to choose unproven but scientifically validated cell
therapy medical innovations, if the researchers are
competent and those seeking treatment are truthful-
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ly and ethically informed. There is a place for both
paradigms in the cell therapy global community.”
Traditionally, innovation in biomedicine has mostly
been linked with academia and translated to indus-
try. In that process, by pre-clinical experimental
approaches, scientists and industry used intuition, ob-
servation and accurate data collection to draw results
that were then further challenged in a relatively
small number of patients. Those human subjects
should be considered extremely precious for both
ethical and business reasons; therefore, they should
be carefully followed during and after the experimen-
tal treatments.
On the contrary, unproven cellular therapy strat-
egies are generally introduced for a larger number of
individuals with the stated intent of rapidly transfer-
ring the laboratory promise to patients without
unacceptable waiting time. In this context, the loose
scientific background together with the lack of basic
scientific method [8] cannot be considered as a spark
for innovation. In fact, after unproven cellular treat-
ments, patients are generally discharged from the clinic
with no or limited follow-up on either possible ben-
efits or side effects. In this way, even if there might
be some positive impact of the procedures, there is
an absolute lack of interest in rigorously observing these
outcomes to generate larger, controlled studies that
are essential in validating hypotheses generated within
clinical trials.
This abrogation of a scientific approach is gener-
ally unclear to patients, who are often given informed
consents to read that can be misleading and result in
the final decision to undertake risky procedures.
Further details on this issue can be found in Part 6,
which deals with communication.
Counteracting distrust due to unproven
cellular therapies
One of the most critical aspects of unproven cellular
therapies—commercial practices—can be related to the
negative impact generated by distrust of cell therapy
approaches. This lack of trust is the consequence of
lack of efficacy and from adverse events. The nega-
tive impact of aversion to innovation will be and has
been felt by regulators, payers, prescribers, and, most
important, in the court of public opinion. The un-
ethical promoting of unproven cellular therapies is also
of particular concern because it is based on unfound-
ed claims and promises and targets vulnerable patients
and families.
Regional economic development strategies are be-
ginning to include accelerated regulatory approval
options as an enticement for investment.This may rep-
resent tightening of standards for unproven cellular
therapies in emerging markets but also reinforces a
competitive regional landscape, bringing therapeutic
sponsors closer to nontraditional regulatory strate-
gies. There are, of course, provisions for accelerated
or conditional regulatory approval for traditional phar-
maceutical products. Heterogeneity in global regulatory
approaches based on accelerated or conditional ap-
proval or, if different tiers of regulation are adopted
in different regions, will inhibit true harmonized de-
velopment of cell therapy products and ultimately
retard development of the field.
The ISCT and related societies are positioned to
work with regulators to implement harmonization of
regulatory structures and to address commercializa-
tion roadblocks and can have significant impact on
controlling public and private sector perspectives on
the cell therapeutic space. Unfortunately, there has been
little progress in this area to date, and for this reason,
we are proposing a series of actions (Table I) to ensure
that patient welfare is kept first and foremost in the
agenda to increase trust regarding cells as therapeu-
tic agents.
The goal is to extend ethical therapeutic
sponsor and regulatory networks globally, such that
incentives for operating outside the mainstream are
Table I. Proposed action steps.
1. Establish a multi-lateral task force comprising patient organizations, professional societies, and regulatory agencies to outline necessary
actions to ensure patients are protected.
2. Implement a long-term program to promote global regulatory harmonization, including (i) early access programs for unmet needs that
permit cost recovery and reimbursement and (ii) regulation that recognizes different tiers of risks and benefit and provides appropriate
levels of regulation.
3. Establish a global, publically accessible cell therapy patient safety registry.
4. Promote rationale scientific development of the field.
5. Enable ethical and compassionate early access to promising cellular therapies.
6. Cooperate with patient, scientific, and professional organizations to leverage and share existing processes and resources with potential
patients.
7. Provide tools to patients that can be used as guidance in evaluating a potential treatment.
8. Establish a reimbursement clearing house to assist early-stage companies that are developing ethical cellular therapies, an inexpensive
source of reimbursement strategy and know-how.
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reduced, and incentives for rational product develop-
ment are in place. This can be achieved without
diminishing economic development drivers or
restricting cultural interests in clinical practice.
If we work together to balance the rights of needy
patients to receive unproven therapies with the pro-
tection of patients and we achieve a relatively
harmonized global regulatory structure, this will benefit
not only patients but also commercial organizations
in the field.
The economics of unproven cellular therapies
One important aspect of this issue is the practicing
physician’s views and behavior. The prescriber has a
responsibility to educate and inform the patient.The
physician or other primary health care provider should
guide the choices of the patient when there are no
available alternatives for the treatment of the patient’s
condition. The physician is there not to decide but
to facilitate and inform decision making and should
not shy away from expressing an opinion on the va-
lidity of some approaches when questioned by the
patient.
If the physician or primary care provider pre-
scribes unproven cellular therapies, this could generate
support for those strategies and the perception that
the approach could be acceptable or validated, despite
the lack of what we normally would consider ade-
quate evidence.This could also create issues in terms
of reimbursement. In fact, a significant driver for un-
proven cellular therapies is the failure of patients to
find promised new medicines reaching reimburse-
ment expectations in traditional health care markets,
driving individual patients to look for economic treat-
ment solutions not accessible under traditional
healthcare plans.
Patients are turning to unproven cellular thera-
pies as an alternative when faced with a gap in
approved therapies in standard of care and reimburse-
ment policy. With approval in traditional markets in
place, an economic driver in seeking nontraditional
treatment remains. It is not unreasonable to antici-
pate medical treatments moving to regions providing
reduced cost treatment—not unlike outsourcing
manufacturing.
Patients certainly have the right to decide where
to obtain treatment, provided they make informed
decisions about the evidence supporting those treat-
ments. There is also no issue when patients elect to
travel to take part in bona fide and ethical clinical
studies.The issue for patients is the manner in which
unproven cellular therapies are sometimes marketed
and promoted, with a minimum of efficacy or even
safety data.
Thus, “medical tourism” is driven by an unmet
market need, and while regions are moving to regu-
late activity, they are also acting to preserve market
segment. Capital incentives to commercialize cell
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therapeutics have become an important driver for re-
gional economic development. Regulatory policy is
becoming a tool to stimulate this regional economic
development, with incentives for accelerating regula-
tory approval or providing access under unproven
cellular therapies at the forefront. A key issue is when
and whether private insurers are going to reimburse
unproven procedures. The health technology assess-
ments supporting reimbursement must rely on
adequately generated and assessed medical evi-
dence, even if sometimes limited, to constrain the use
of unproven cellular therapies and further support pro-
vision of quality medical treatments.
A call for a new global multilateral
collaborative framework
Few professional societies have taken action on un-
proven cellular therapies. The International Society
for Stem Cell Research has published patient guide-
lines for stem cell therapies [9], and ISCT has
published a paper on the subject [7] and conducted
several public workshops. In addition, the U.S. Na-
tional Institutes of Health has published a web-
based tool on stem cell therapies [10]. Unfortunately,
the impact of these efforts has probably been minimal
because most patients do not read the scientific
journals or visit the society or government websites.
In addition, there may be a perception that profes-
sional societies are excessively pro-industry and that
their pleas for more regulation are based on
anticompetitive interests rather than altruism and true
patient concern.
Although bone marrow transplantation, as a par-
adigm for cell delivery in humans, has been used for
almost 60 years now [11], the field of cellular therapy
is still relatively young. Even so, a surprisingly large
number of translational organizations have devel-
oped in the field, most of which have unique missions
but also many overlapping interests. Unfortunately,
there has been little cooperation among the cellular
therapy organizations to date. What is needed is a
broad alliance of the various players in the field. To
enhance credibility and ensure that a patient’s inter-
ests and rights are preserved, it is essential to include
patients and patient organizations in this alliance.
The alliance would need to balance the rights of
patients to obtain treatment with the rights of pa-
tients to participate in an ethical informed consent
process, where all relevant risks and potential ben-
efits are disclosed. Without patient leadership, the
alliance may be accused of bias toward large com-
mercial players in the industry. It is our hope that,
working together with a coalition of stakeholders, we
can fulfill this vision of a broad, pro-patient alliance
in the near future.
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